A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
- Conditions
- HIV Infections
- Registration Number
- NCT00002423
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
This study will compare the safety and effectiveness of two anti-HIV drug combinations in fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with other anti-HIV drug treatments.
- Detailed Description
Patients experiencing virologic failure while receiving an IDV-containing antiretroviral regimen will receive the 3TC/ABC/APV/NFV combination. Patients experiencing virologic failure while receiving an NFV-containing antiretroviral regimen will receive the 3TC/ABC/APV/IDV combination.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Saint Francis Mem Hosp
🇺🇸San Francisco, California, United States
Georgetown Univ Med Ctr
🇺🇸Washington, District of Columbia, United States
IDC Research Initiative
🇺🇸Altamonte Springs, Florida, United States
Natl Institute of Allergy and Infectious Diseases
🇺🇸Bethesda, Maryland, United States
Kansas City AIDS Research Consortium
🇺🇸Kansas City, Missouri, United States
Bentley-Salick Med Practice
🇺🇸New York, New York, United States
Associates in Med and Mental Health
🇺🇸Tulsa, Oklahoma, United States
Portland Veterans Adm Med Ctr / Rsch & Education Grp
🇺🇸Portland, Oregon, United States
Saint Francis Mem Hosp🇺🇸San Francisco, California, United States